• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

20/20 Biolabs, Inc. - Common Stock (NQ:AIDX)

0.1571 -0.0235 (-13.01%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 309,141
Open 0.1802
Bid (Size) 0.1522 (25,000)
Ask (Size) 0.1637 (1,000)
Prev. Close 0.1806
Today's Range 0.1556 - 0.1803
52wk Range 0.1556 - 50.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
20/20 BioLabs Reports Third Quarter 2026 Financial Results and Recent Business Updates
November 16, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
REMINDER TO VOTE: 20/20 BioLabs Special Meeting of Stockholders to Be Held December 9, 2026
November 05, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire

Performance

52-Week Range 99.7% below 52-week high
0.1571
0.1652W Low 50.0052W High
1 Week 23.7% below 1-week high
0.161W Low 0.211W High

20/20 Biolabs, Inc. - Common Stock (AIDX) traded between $0.16 and $50.00 over the past 52 weeks and last traded at $0.16, 99.7% below its 52-week high. Over the past week it ranged between $0.16 and $0.21.

Past 12 Months
-15.1%
-41.9%
-71.7%
-84.0%
-99.3%
-99.3%
1W -$0.03
1M -$0.11
3M -$0.40
6M -$0.82
YTD -$23.69
1Y -$23.69

AIDX was -99.3% over the past year, -84.0% over six months, -99.3% year to date, -15.1% in the last week.

12 Months vs Market
AIDX
-99.3%
DIA
+5.0%
SPY
+5.7%
QQQ
+3.9%
IWM
+12.0%

Over the past 12 months AIDX returned -99.3% versus DIA (Dow) +5.0%, SPY (S&P 500) +5.7%, QQQ (Nasdaq 100) +3.9% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 2.19× 3-mo avg
Today 309,141 3-mo avg 141.0K
1W
147.8K
1M
218.4K
3M
141.0K
6M
472.1K
YTD
386.9K
1Y
386.9K

AIDX most recently traded 309,141 shares against a 3-month average daily volume of 141.0K.

More News

Read More
News headline image
20/20 BioLabs to Host November 4 Investor Webinar on OneTest™ Commercial Expansion and Growth Strategy
October 29, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
October 02, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model
September 29, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
August 28, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
August 26, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
August 17, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour
July 30, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
July 27, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock
July 23, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth
July 09, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month
June 22, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
Monday's session: top gainers and losers ↗
June 15, 2026
Via Chartmill
Gapping stocks in Monday's session ↗
June 15, 2026
Via Chartmill
Monday's pre-market session: top gainers and losers ↗
June 15, 2026
Via Chartmill
Get insights into the top gainers and losers of Friday's after-hours session. ↗
June 12, 2026
Via Chartmill
News headline image
20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters
May 27, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
May 22, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress
May 20, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina
May 12, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
April 10, 2026
Via ACCESS Newswire
News headline image
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform
April 07, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
March 31, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire
News headline image
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test
March 27, 2026
From 20/20 Biolabs Inc.
Via GlobeNewswire

Frequently Asked Questions

Is 20/20 Biolabs, Inc. - Common Stock publicly traded?
Yes, 20/20 Biolabs, Inc. - Common Stock is publicly traded.
What exchange does 20/20 Biolabs, Inc. - Common Stock trade on?
20/20 Biolabs, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for 20/20 Biolabs, Inc. - Common Stock?
The ticker symbol for 20/20 Biolabs, Inc. - Common Stock is AIDX on the Nasdaq Stock Market
What is the current price of 20/20 Biolabs, Inc. - Common Stock?
The current price of 20/20 Biolabs, Inc. - Common Stock is 0.1571
When was 20/20 Biolabs, Inc. - Common Stock last traded?
The last trade of 20/20 Biolabs, Inc. - Common Stock was at 11/20/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap